Skip to main content
VIYASH SCIENTIFIC LIMITED logo

VIYASH SCIENTIFIC LIMITED — Investor Relations & Filings

Ticker · VIYASH ISIN · INE807F01027 LEI · 335800SXM7D3VSHF2X07 BSE.NS Manufacturing
Open in API
Filings indexed 1,420 across all filing types
Latest filing 2025-11-19 M&A Activity
Country IN India
Listing BSE.NS VIYASH

About VIYASH SCIENTIFIC LIMITED

https://www.viyash.com

Viyash Scientific Limited is an integrated pharmaceutical platform specializing in the development and manufacturing of Active Pharmaceutical Ingredients (APIs), advanced intermediates, and finished dosage forms. The organization operates a network of manufacturing facilities supported by robust research and development capabilities, focusing on complex chemistry and niche therapeutic segments. Its core business activities encompass the entire pharmaceutical value chain, from process development and scale-up to commercial-scale production. The company provides integrated solutions to global partners, leveraging its technical expertise in chemical synthesis and commitment to international quality standards. By maintaining a focus on operational excellence and innovation, the company serves as a strategic partner in the global healthcare supply chain, delivering high-quality medicinal components and formulations.

Recent filings

Filing Released Lang Actions
Written order of NCLT, Hyderabad Bench.
M&A Activity Classification · 95% confidence The document is a detailed legal order from the National Company Law Tribunal (NCLT) Hyderabad bench regarding a composite scheme of amalgamation involving Sequent Scientific Limited and multiple other companies. It references the Companies Act, 2013, and the Companies (Compromises, Arrangements and Amalgamation) Rules, 2016. The document includes the order sanctioning the scheme, details of the companies involved, their registered offices, share capital, and other legal particulars. This is a formal legal proceeding document related to a merger/amalgamation scheme. It is not a financial report, earnings release, or management discussion. It is not a proxy statement or voting result announcement. It is not a regulatory filing in the sense of compliance or officer certification but a legal proceeding order. Therefore, the most appropriate classification is "M&A Activity (TAR)" which covers announcements and documents related to merger proposals or takeover bids, including court orders sanctioning such schemes.
2025-11-19 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a detailed communication from Sequent Scientific Limited dated November 18, 2025, addressed to stock exchanges, referencing a composite scheme of amalgamation (merger) approved by the National Company Law Tribunal (NCLT). It includes a press release about the merger, detailed financial performance data for Q2 FY26 and H1 FY26, pro forma combined financials, synergy updates, and an investor presentation. The content focuses on merger approval, combined financial results, strategic outlook, and operational updates related to the merger. There is no indication that this is a full annual or quarterly report, nor is it a simple announcement or certification. The presence of detailed financial data, merger process updates, and an investor presentation strongly indicates this is a Capital/Financing Update (CAP) filing related to merger and financing activities. Therefore, the document is best classified as a Capital/Financing Update (CAP).
2025-11-18 English
Updated Investor Presentation
M&A Activity Classification · 95% confidence The document is a detailed communication from Sequent Scientific Limited dated November 18, 2025, addressed to stock exchanges and investors. It discusses the approval of a composite scheme of amalgamation (merger) by the National Company Law Tribunal (NCLT) involving Sequent Scientific and multiple other companies including Viyash Lifesciences. The document includes a press release and an extensive investor presentation with financial highlights, pro forma combined financials, synergy updates, and merger process status. The content focuses on merger approval, combined financial performance, strategic outlook, and operational synergies. There is no indication that this is a full annual or quarterly report, audit report, or earnings release. Instead, it is a comprehensive update on a merger transaction and related investor information. Therefore, the document best fits the category of M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids. The length and detail confirm it is not merely an announcement but a substantive filing about the merger.
2025-11-18 English
Press Release and updated Investor presentation
Investor Presentation Classification · 95% confidence The document is a detailed communication dated November 18, 2025, from Sequent Scientific Limited to stock exchanges, referencing a composite scheme of amalgamation (merger) approved by the National Company Law Tribunal (NCLT). It includes a press release and an extensive investor presentation with financial performance highlights, pro forma combined financials, synergy updates, and merger process status. The content focuses on the merger approval, combined financial results, strategic outlook, and operational synergies. It is not merely an announcement of the merger approval but contains substantive financial data and analysis related to the merger. The presence of detailed financial tables, performance metrics, and strategic commentary aligns with the characteristics of an Investor Presentation (IP). It is not a full Annual Report (10-K), Earnings Release (ER), or Merger & Acquisition filing (MA) such as a proxy or tender offer statement. The document is too detailed and lengthy to be a simple Regulatory Filing (RNS) or Report Publication Announcement (RPA). Therefore, the most appropriate classification is Investor Presentation (IP).
2025-11-18 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is a detailed communication from Sequent Scientific Limited dated November 18, 2025, addressed to stock exchanges and investors. It discusses the approval of a composite scheme of amalgamation (merger) by the National Company Law Tribunal (NCLT), including references to previous disclosures and the awaited formal order. The document includes a press release and an updated investor presentation with extensive financial data, pro forma combined financials, synergy updates, and merger process status. The content focuses on the merger event, combined financial performance, strategic rationale, and operational synergies. It is not merely an announcement of a report but contains substantive financial and operational information related to the merger. The presence of detailed financial metrics, combined P&L and balance sheet snapshots, and forward-looking synergy plans aligns with the characteristics of an Investor Presentation (IP) rather than a simple regulatory filing or announcement. Therefore, the document is best classified as an Investor Presentation (IP).
2025-11-18 English
Intimation of the pronouncement by Hon"ble NCLT , Hyderabad bench approving composite scheme of amalgamation
M&A Activity Classification · 95% confidence The document is a detailed communication from Sequent Scientific Limited dated November 18, 2025, addressed to stock exchanges and investors. It discusses the approval of a composite scheme of amalgamation (merger) by the National Company Law Tribunal (NCLT) involving Sequent Scientific and multiple other companies including Viyash Lifesciences. The document includes a press release and an extensive investor presentation with financial highlights, pro forma combined financials, synergy updates, and merger process status. The content focuses on the merger approval, combined financial performance, strategic outlook, and operational synergies. There is no indication that this is a full annual or quarterly report, nor is it a simple announcement of a report publication. The presence of detailed financial data, merger process details, and strategic commentary aligns with the category of M&A Activity filings, which cover announcements and documents related to merger proposals or takeover bids. Therefore, the document should be classified as M&A Activity (Code: TAR).
2025-11-18 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.